Skip to main content

Table 1 Main clinical features according to Nestin status in patients with advance HCC (n = 220)

From: Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance

Clinical and pathological indexes

 

Nestin expression

 

Total

Low

High

P

n

n (%)

n (%)

 

Age (years)

≤ 60

118

52(44.1)

66(55.9)

0.119

 

> 60

102

54(52.9)

48(47.1)

 

Gender

Male

109

49(45.0)

60(55.0)

0.208

 

Female

111

57(51.4)

54(48.6)

 

HBsAg

Negative

120

59(49.2)

61(50.8)

0.427

 

Positive

100

47(47.0)

53(53.0)

 

Albumin

≤ 35 g/L

124

57(46.0)

67(54.0)

0.498

 

> 35 g/L

96

49(51.0)

47(49.0)

 

Liver cirrhosis

Absent

73

40(54.8)

33(45.2)

0.107

 

Present

147

66(44.9)

81(55.1)

 

Child-Pugh stage

A

120

57(47.5)

63(52.5)

0.466

 

B

100

49(49.0)

51(51.0)

 

AFP (ng/ml)

≤ 20

77

35(45.5)

42(54.5)

0.326

 

> 20

143

71(49.7)

72(50.3)

 

Edmondson-Steiner grade

I-II

96

52(54.2)

44(45.8)

0.077

 

III-IV

124

54(43.5)

70(56.5)

 

Macroscopic vascular invasion

Absent

104

61(58.7)

43(41.3)

0.002 *

 

Present

116

45(38.8)

71(61.2)

 

BCLC stage

B

86

52(60.5)

34(39.5)

0.003 *

 

C

134

54(40.3)

80(59.7)

 

Disease status

Confined to the liver

100

57(57.0)

43(43.0)

0.012 *

 

Metastatic disease

120

49(40.8)

71(59.2)

 
  1. Abbreviations: BCLC stage Barcelona Clinic Liver Cancer
  2. *significant difference is shown in bold